Table 1

Patient characteristics at baseline

CharacteristicValue
No. of subjects enrolled 60 
Median age, y (range) 70.1 (40.4-87.2) 
Sex, n (%)  
    Male 28 (46.7) 
    Female 32 (53.3) 
Race, n (%)  
    White 53 (88.3) 
    Black 4 (6.7) 
    Hispanic 2 (3.3) 
    Other 1 (1.7) 
Eastern Cooperative Oncology Group performance status*  
    0 33 (55.0) 
    1 27 (45.0) 
Laboratory values  
    Normal hemoglobin 35 (58.3) 
    Normal LDH 44 (73.3) 
Stage  
    IE-IIE 4 (6.7) 
    III 15 (25.0) 
    IIIE 2 (3.3) 
    IV 39 (65.0) 
Histology  
    Follicular center cell, grade 1 23 (38.3) 
    Follicular center cell, grade 2 17 (28.3) 
    Small lymphocytic 12 (20.0) 
    Marginal zone, extranodal 5 (8.3) 
    Marginal zone, nodal 2 (3.3) 
    Unspecified 1 (1.7) 
Prior therapy  
    Chemotherapy 60 (100) 
    Hormone/biologic therapy 1 (1.7) 
    Radiotherapy 13 (21.7) 
Sites of metastasis  
    Soft tissue/lymph node(s) 59 (98.3) 
    Viscera 21 (35.0) 
    Bone 16 (26.7) 
CharacteristicValue
No. of subjects enrolled 60 
Median age, y (range) 70.1 (40.4-87.2) 
Sex, n (%)  
    Male 28 (46.7) 
    Female 32 (53.3) 
Race, n (%)  
    White 53 (88.3) 
    Black 4 (6.7) 
    Hispanic 2 (3.3) 
    Other 1 (1.7) 
Eastern Cooperative Oncology Group performance status*  
    0 33 (55.0) 
    1 27 (45.0) 
Laboratory values  
    Normal hemoglobin 35 (58.3) 
    Normal LDH 44 (73.3) 
Stage  
    IE-IIE 4 (6.7) 
    III 15 (25.0) 
    IIIE 2 (3.3) 
    IV 39 (65.0) 
Histology  
    Follicular center cell, grade 1 23 (38.3) 
    Follicular center cell, grade 2 17 (28.3) 
    Small lymphocytic 12 (20.0) 
    Marginal zone, extranodal 5 (8.3) 
    Marginal zone, nodal 2 (3.3) 
    Unspecified 1 (1.7) 
Prior therapy  
    Chemotherapy 60 (100) 
    Hormone/biologic therapy 1 (1.7) 
    Radiotherapy 13 (21.7) 
Sites of metastasis  
    Soft tissue/lymph node(s) 59 (98.3) 
    Viscera 21 (35.0) 
    Bone 16 (26.7) 
*

Assessed before first treatment.

Subjects may have had more than 1 type of prior therapy.

Patients may have had more that 1 site of metastasis.

Close Modal

or Create an Account

Close Modal
Close Modal